ALBPS — Biophytis SA Share News
0.000.00%
Last trade - 00:00Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon
Brief: Biophytis Shares Suspended Prior Completion Of Refinancing Transaction
Brief: Biophytis Extends Its Contract With Atlas To Secure Financing For Its Business Activities
Brief: Biophytis SA Announces Design Of Its Phase 2 Oba Clinical Study In Obesity
Brief: Biophytis SA Looking To Licence-Out BI0101 To Regional Or Global Pharmaceutical Cos
Brief: Biophytis Announces Transfer Of ADSs To OTC Market
Brief: Biophytis Announces Ratio Change Under ADR Program
Brief: Biophytis Says Company Believes That It Will Be Able To Finance Its Activities Until Q1 Of 2025
Brief: Biophytis Launches OBA Phase 2 Clinical Study In Obesity With Bio101 (20-Hydroxyecdysone)
Brief: Biophytis SA Says Co And The University Of Liège Explore The Potential Of Sarconeos (Bio101) In The Treatment Of Viral Respiratory Failure
Brief: Biophytis Says Nasdaq Notice Letter Has No Immediate Effect On Listing Of ADSS
Brief: Biophytis And Innovation Solutions Pharma Sign A Partnership Agreement To Accelerate Market Access For Sarconeos (Bio101) In Brazil
Brief: Biophytis Receives Notice Of Delisting From Nasdaq And Announces It Will Request A Hearing Before The Nasdaq Hearings Panel
Brief: Biophytis SA Says Half-Year Loss Has Been Significantly Reduced, From EUR 12.4 Million At 30 June 2022 To EUR 7.8 Million At 30 June 2023
Brief: Biophytis And Skyepharma Sign Partnership For Sarconeos Production
Advisory: Alert on Biophytis H1 operating loss withdrawn